Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
← catalyst calendarNCT05798897 · readout in 558 d
Sponsored by Marker Therapeutics, Inc. (industry) · MRKR — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
79estimated
Sites
7
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-02 | actual | When the study began enrolling |
| Primary completion | 2028-02-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-02-28 | estimated | The whole study's end, after follow-up |
| First posted | 2023-04-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non-Hodgkin Lymphoma, Adult
- Non-Hodgkin Lymphoma, Refractory
- Non-Hodgkin Lymphoma, Relapsed
- Non Hodgkin Lymphoma
- Hodgkin Lymphoma
- Hodgkin Lymphoma, Adult
- Hodgkin's Lymphoma, Relapsed, Adult
Intervention
- Drug: MT-601
Primary outcomes
what the primary-completion date above is the date OFDose Escalation
measured After 3 or 6 patients in each dose cohort have been treated with MT-601 and have had the opportunity to be followed for 28 days.
Dose Expansion (ORR)
measured 12 months after the last patient treated in the Dose Expansion portion of the study receiving the first dose of MT-601.
Dose Expansion (DOR)
measured 12 months after the last patient treated in the Dose Expansion portion of the study receiving the first dose of MT-601.
Dose Expansion (CR)
measured 12 months after the last patient treated in the Dose Expansion portion of the study receiving the first dose of MT-601.
Permalink · MRKR's whole pipeline · Catalyst calendar · Every registered study · What changed